[F-18] Fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases
Version of Record online: 24 NOV 2003
Copyright © 2003 Wiley-Liss, Inc.
Journal of Surgical Oncology
Volume 84, Issue 4, pages 215–223, December 2003
How to Cite
Donckier, V., Van Laethem, J. L., Goldman, S., Van Gansbeke, D., Feron, P., Ickx, B., Wikler, D. and Gelin, M. (2003), [F-18] Fluorodeoxyglucose positron emission tomography as a tool for early recognition of incomplete tumor destruction after radiofrequency ablation for liver metastases. J. Surg. Oncol., 84: 215–223. doi: 10.1002/jso.10314
- Issue online: 24 NOV 2003
- Version of Record online: 24 NOV 2003
- Manuscript Accepted: 24 SEP 2003
- RadioTherapeutics Corp. (a research grant for clinical study and data management)
Background and Objectives
To assess the value of FDG positron emission tomography (PET) for early detection of incomplete tumor destruction after radiofrequency ablation (RFA) for liver metastasis.
Twenty-eight unresectable liver metastases in 17 patients were treated by RFA. Patients underwent computed tomography (CT) and FDG-PET preoperatively, at 1 week, 1 month, and 3 months postoperatively. Postoperative CT and FDG-PET at 1 week and 1 month were analyzed to identify hypervascular and hypermetabolic residual tumors at the RFA site. These results were correlated with follow-up CT and, in case of reintervention, with pathologic results.
In 24/28 of RFA-treated metastases, CT and FDG-PET at 1 week and 1 month showed no tumor residues. During follow-up, none of these 13 patients developed local recurrence at RFA site. In four patients, FDG-PET at 1 week and 1 month showed peripheral hypermetabolic residue after RFA, whereas CT did not revealed residual tumor. In three patients, local persistence of viable tumor cells was biopsy-proven at reintervention. In the fourth, follow-up CT showed subsequent development of a local recurrence.
FDG-PET accurately monitors the local efficacy of RFA for treatment of liver metastases, as it early recognizes incomplete tumor ablation, not detectable on CT. J. Surg. Oncol. 2003;84:215–223. © 2003 Wiley-Liss, Inc.